https://mma.prnewswire.com/media/2598258/THE_ROSEN_LAW_FIRM_P_A_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of CarMax, Inc. (NYSE: KMX) between June 20, 2025 and November 5, 2025, both dates inclusive (the “Class Period”), of the important January 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If […]

(NasdaqGM:GPCR), SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced plans to release topline data from its ACCESS clinical program of aleniglipron, the company's once-daily oral small molecule GLP-1 receptor

Structure Therapeutics to Report Data from ACCESS Clinical Program of Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron, on December 8, 2025 GlobeNewswire December 07, 2025 SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus

(NASDAQ:IMMX), LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 19,117,646 shares of its common stock at a price to the public of $5.10 per share, and to

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants GlobeNewswire December 07, 2025 LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering

New York, New York–(Newsfile Corp. – December 7, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of investors in cryptocurrency issued by Balancer (ticker: BAL), resulting from allegations that Balancer may have issued materially misleading business information to the investing public. SO

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis GlobeNewswire December 07, 2025 – NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four

Ongoing strategic review has resulted in divestitures generating significant proceeds, simplifying Matthews' business mix and strengthening its balance sheet Confirms receipt of another notice of director nominations from Barington, less than one year after Barington unsuccessfully ran a proxy contest at the 2025 annual meeting Matthews' shareholder proposals will include board declassification and the adoption

NEW YORK CITY, NY / ACCESS Newswire / December 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Stride, Inc. ("Stride" or the "Company") (NYSE:LRN).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

NEW YORK, NY, NY / ACCESS Newswire / December 7, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against WPP Plc ("WPP" or the "Company") (NYSE:WPP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged